REG - Physiomics PLC - Notice of Results and Investor Presentation

PhysiomicsAnnouncement

19/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240919:nRSS7700Ea&default-theme=true

RNS Number : 7700E  Physiomics PLC  19 September 2024

19 September 2024

 

 

Physiomics plc

("Physiomics" or the "Company")

 

 

Notice of Results and Investor Presentation via Investor Meet Company

 

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it expects to release its
audited results for the financial year ended 30 June 2024 during the last week
of September 2024.

 

Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide
a live presentation relating to the Company's full year results and wider
business update via Investor Meet Company on 7 October 2024 at noon BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until 6
October 2024, 09:00 am BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
PHYSIOMICS PLC via:

 

https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://url6.mailanyone.net/scanner?m=1rfyxY-00048v-50&d=4%7Cmail%2F90%2F1709284200%2F1rfyxY-00048v-50%7Cin6r%7C57e1b682%7C24907477%7C9801997%7C65E19C4412C2B5D60E51131D9BCA75C0&o=%2Fphtw%3A%2Fwtstnw.resoivptmenomaechoy.s%2Fpycmpiiocs-lmceg%2Fr-streirotsevni&s=c2XnNeMo69ti-YrBKbGiRMbBLaQ)

 

Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGMLNRNGDZM